Effect of N-arachidonoyl-L-serine on human cerebromicrovascular endothelium

Tomoyuki Kino, Toshiki Tomori, Rania Abutarboush, Paola Castri, Ye Chen, Frederick Lenz, Richard M. McCarron, Maria Spatz

Research output: Contribution to journalArticle

Abstract

N-arachidonoyl-L-serine (ARA-S) is an endogenous lipid, chemically related to the endocannabinoid, N-arachidonoyl ethanolamine (i.e., anandamide) and with similar physiologic and pathophysiologic functions. Reports indicate that ARA-S possesses vasoactive and neuroprotective properties resembling those of cannabinoids. However, in contrast to cannabinoids, ARA-S binds weakly to its known classical receptors, CB1 and CB2, and is therefore considered to be a ‘cannabinoid-like’ substance. The originally described ARA-S induced-endothelial-dependent vasorelaxation was not abrogated by CB1, CB2 receptor antagonists or TRPV1 competitive inhibitor. The present report demonstrates that ARA-S enhances the fluorescence staining of both cannabinoid receptors (CB1 and CB2) in human brain endothelial cells (HBEC). This reaction is specific since it was reduced by respective selective receptor antagonist (SR141716A and SR141728A). ARA-S alone or in the presence of ET-1 was shown to alter the cytoskeleton (actin). Both ARA-S stimulated phosphorylation of various kinases (MAPK, Akt, JNK and c-JUN) and alteration of cytoskeleton are mediated via CB1, CB2 and TRPV1 receptors. The findings also showed the involvement of Rho/Rock and PI3/Akt/NO pathways in the ARA-S-induced phosphorylation of kinases and actin reorganization in HBEC. All of the above mentioned ARA-S-induced effects were reduced by the treatment with LY294002 (inhibitor of PI3/Akt kinase), except MAPK kinase. In addition, MAPK, JNK, c-JUN phosphorylation were inhibited by H1152 (inhibitor of Rho/ROCK kinase), except Akt kinase. Furthermore, PI3/Akt pathway was inhibited by pretreatment with L-NAME (inhibitor of NOS). The findings suggest that ARA-S is a modulator of Rho kinase and may play a critical role in the regulation of its activity and subsequent effects on the cytoskeleton and its role in supporting essential cell functions like vasodilation, proliferation and movement.

Original languageEnglish (US)
Pages (from-to)254-260
Number of pages7
JournalBiochemistry and Biophysics Reports
Volume8
DOIs
StatePublished - Dec 1 2016

Fingerprint

Endothelium
Cannabinoid Receptor CB2
Cannabinoid Receptor CB1
Phosphorylation
Cannabinoids
rho-Associated Kinases
rimonabant
Mitogen-Activated Protein Kinase Kinases
Endothelial cells
Cytoskeleton
Vasodilation
Brain
Phosphotransferases
Endothelial Cells
N-arachidonoyl L-serine
Endocannabinoids
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Ethanolamine
NG-Nitroarginine Methyl Ester
Actin Cytoskeleton

Keywords

  • Cannabinoid-like agent
  • Cytoskeleton
  • Endothelin-1
  • Human brain endothelial cells
  • N-arachidonoyl-L-serine
  • Signal transduction pathway

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Effect of N-arachidonoyl-L-serine on human cerebromicrovascular endothelium. / Kino, Tomoyuki; Tomori, Toshiki; Abutarboush, Rania; Castri, Paola; Chen, Ye; Lenz, Frederick; McCarron, Richard M.; Spatz, Maria.

In: Biochemistry and Biophysics Reports, Vol. 8, 01.12.2016, p. 254-260.

Research output: Contribution to journalArticle

Kino, T, Tomori, T, Abutarboush, R, Castri, P, Chen, Y, Lenz, F, McCarron, RM & Spatz, M 2016, 'Effect of N-arachidonoyl-L-serine on human cerebromicrovascular endothelium', Biochemistry and Biophysics Reports, vol. 8, pp. 254-260. https://doi.org/10.1016/j.bbrep.2016.09.002
Kino, Tomoyuki ; Tomori, Toshiki ; Abutarboush, Rania ; Castri, Paola ; Chen, Ye ; Lenz, Frederick ; McCarron, Richard M. ; Spatz, Maria. / Effect of N-arachidonoyl-L-serine on human cerebromicrovascular endothelium. In: Biochemistry and Biophysics Reports. 2016 ; Vol. 8. pp. 254-260.
@article{19c9c9223a5b4ac9b1c523cc24cd17c9,
title = "Effect of N-arachidonoyl-L-serine on human cerebromicrovascular endothelium",
abstract = "N-arachidonoyl-L-serine (ARA-S) is an endogenous lipid, chemically related to the endocannabinoid, N-arachidonoyl ethanolamine (i.e., anandamide) and with similar physiologic and pathophysiologic functions. Reports indicate that ARA-S possesses vasoactive and neuroprotective properties resembling those of cannabinoids. However, in contrast to cannabinoids, ARA-S binds weakly to its known classical receptors, CB1 and CB2, and is therefore considered to be a ‘cannabinoid-like’ substance. The originally described ARA-S induced-endothelial-dependent vasorelaxation was not abrogated by CB1, CB2 receptor antagonists or TRPV1 competitive inhibitor. The present report demonstrates that ARA-S enhances the fluorescence staining of both cannabinoid receptors (CB1 and CB2) in human brain endothelial cells (HBEC). This reaction is specific since it was reduced by respective selective receptor antagonist (SR141716A and SR141728A). ARA-S alone or in the presence of ET-1 was shown to alter the cytoskeleton (actin). Both ARA-S stimulated phosphorylation of various kinases (MAPK, Akt, JNK and c-JUN) and alteration of cytoskeleton are mediated via CB1, CB2 and TRPV1 receptors. The findings also showed the involvement of Rho/Rock and PI3/Akt/NO pathways in the ARA-S-induced phosphorylation of kinases and actin reorganization in HBEC. All of the above mentioned ARA-S-induced effects were reduced by the treatment with LY294002 (inhibitor of PI3/Akt kinase), except MAPK kinase. In addition, MAPK, JNK, c-JUN phosphorylation were inhibited by H1152 (inhibitor of Rho/ROCK kinase), except Akt kinase. Furthermore, PI3/Akt pathway was inhibited by pretreatment with L-NAME (inhibitor of NOS). The findings suggest that ARA-S is a modulator of Rho kinase and may play a critical role in the regulation of its activity and subsequent effects on the cytoskeleton and its role in supporting essential cell functions like vasodilation, proliferation and movement.",
keywords = "Cannabinoid-like agent, Cytoskeleton, Endothelin-1, Human brain endothelial cells, N-arachidonoyl-L-serine, Signal transduction pathway",
author = "Tomoyuki Kino and Toshiki Tomori and Rania Abutarboush and Paola Castri and Ye Chen and Frederick Lenz and McCarron, {Richard M.} and Maria Spatz",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.bbrep.2016.09.002",
language = "English (US)",
volume = "8",
pages = "254--260",
journal = "Biochemistry and Biophysics Reports",
issn = "2405-5808",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Effect of N-arachidonoyl-L-serine on human cerebromicrovascular endothelium

AU - Kino, Tomoyuki

AU - Tomori, Toshiki

AU - Abutarboush, Rania

AU - Castri, Paola

AU - Chen, Ye

AU - Lenz, Frederick

AU - McCarron, Richard M.

AU - Spatz, Maria

PY - 2016/12/1

Y1 - 2016/12/1

N2 - N-arachidonoyl-L-serine (ARA-S) is an endogenous lipid, chemically related to the endocannabinoid, N-arachidonoyl ethanolamine (i.e., anandamide) and with similar physiologic and pathophysiologic functions. Reports indicate that ARA-S possesses vasoactive and neuroprotective properties resembling those of cannabinoids. However, in contrast to cannabinoids, ARA-S binds weakly to its known classical receptors, CB1 and CB2, and is therefore considered to be a ‘cannabinoid-like’ substance. The originally described ARA-S induced-endothelial-dependent vasorelaxation was not abrogated by CB1, CB2 receptor antagonists or TRPV1 competitive inhibitor. The present report demonstrates that ARA-S enhances the fluorescence staining of both cannabinoid receptors (CB1 and CB2) in human brain endothelial cells (HBEC). This reaction is specific since it was reduced by respective selective receptor antagonist (SR141716A and SR141728A). ARA-S alone or in the presence of ET-1 was shown to alter the cytoskeleton (actin). Both ARA-S stimulated phosphorylation of various kinases (MAPK, Akt, JNK and c-JUN) and alteration of cytoskeleton are mediated via CB1, CB2 and TRPV1 receptors. The findings also showed the involvement of Rho/Rock and PI3/Akt/NO pathways in the ARA-S-induced phosphorylation of kinases and actin reorganization in HBEC. All of the above mentioned ARA-S-induced effects were reduced by the treatment with LY294002 (inhibitor of PI3/Akt kinase), except MAPK kinase. In addition, MAPK, JNK, c-JUN phosphorylation were inhibited by H1152 (inhibitor of Rho/ROCK kinase), except Akt kinase. Furthermore, PI3/Akt pathway was inhibited by pretreatment with L-NAME (inhibitor of NOS). The findings suggest that ARA-S is a modulator of Rho kinase and may play a critical role in the regulation of its activity and subsequent effects on the cytoskeleton and its role in supporting essential cell functions like vasodilation, proliferation and movement.

AB - N-arachidonoyl-L-serine (ARA-S) is an endogenous lipid, chemically related to the endocannabinoid, N-arachidonoyl ethanolamine (i.e., anandamide) and with similar physiologic and pathophysiologic functions. Reports indicate that ARA-S possesses vasoactive and neuroprotective properties resembling those of cannabinoids. However, in contrast to cannabinoids, ARA-S binds weakly to its known classical receptors, CB1 and CB2, and is therefore considered to be a ‘cannabinoid-like’ substance. The originally described ARA-S induced-endothelial-dependent vasorelaxation was not abrogated by CB1, CB2 receptor antagonists or TRPV1 competitive inhibitor. The present report demonstrates that ARA-S enhances the fluorescence staining of both cannabinoid receptors (CB1 and CB2) in human brain endothelial cells (HBEC). This reaction is specific since it was reduced by respective selective receptor antagonist (SR141716A and SR141728A). ARA-S alone or in the presence of ET-1 was shown to alter the cytoskeleton (actin). Both ARA-S stimulated phosphorylation of various kinases (MAPK, Akt, JNK and c-JUN) and alteration of cytoskeleton are mediated via CB1, CB2 and TRPV1 receptors. The findings also showed the involvement of Rho/Rock and PI3/Akt/NO pathways in the ARA-S-induced phosphorylation of kinases and actin reorganization in HBEC. All of the above mentioned ARA-S-induced effects were reduced by the treatment with LY294002 (inhibitor of PI3/Akt kinase), except MAPK kinase. In addition, MAPK, JNK, c-JUN phosphorylation were inhibited by H1152 (inhibitor of Rho/ROCK kinase), except Akt kinase. Furthermore, PI3/Akt pathway was inhibited by pretreatment with L-NAME (inhibitor of NOS). The findings suggest that ARA-S is a modulator of Rho kinase and may play a critical role in the regulation of its activity and subsequent effects on the cytoskeleton and its role in supporting essential cell functions like vasodilation, proliferation and movement.

KW - Cannabinoid-like agent

KW - Cytoskeleton

KW - Endothelin-1

KW - Human brain endothelial cells

KW - N-arachidonoyl-L-serine

KW - Signal transduction pathway

UR - http://www.scopus.com/inward/record.url?scp=84989201880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989201880&partnerID=8YFLogxK

U2 - 10.1016/j.bbrep.2016.09.002

DO - 10.1016/j.bbrep.2016.09.002

M3 - Article

C2 - 28955964

AN - SCOPUS:84989201880

VL - 8

SP - 254

EP - 260

JO - Biochemistry and Biophysics Reports

JF - Biochemistry and Biophysics Reports

SN - 2405-5808

ER -